Google DeepMind spinoff, Isomorphic, announced its latest $2.1 billion funding, which will be used to advance ​practical applications of AI in the healthcare sector and to re-imagine drug discovery. The funding round, with an undisclosed valuation, was led by Thrive Capital. "This capital injection allows us...[to move] forward in our mission to solve all diseases," said CEO Demis Hassabis.